Advertisement

Prevention of coronary heart disease and risk of cholelithiasis

  • G. C. Urbinati
  • the GREPCO Group

Abstract

Certain clinical and experimental observations appear to indicate that dietary1–3 and/or pharmacological4,5 measures aimed at reducing metabolic risk factors of coronary heart disease (first and foremost cholesterolaemia) may alter bile composition thus favouring gallstone formation. Epidemio-logical data, too, seem to point in this direction although they are not univocal6–10.

Keywords

Coronary Heart Disease Cholic Acid Gallstone Disease Biliary Lipid Coronary Heart Disease Prevention 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Grundy, S. M. (1975). Effects of polyunsaturated fats on lipid metabolism in patients with hypertriglyceridemia. J. Clin. Invest., 51, 273–292Google Scholar
  2. 2.
    Lewis, B. (1958). Effect of certain dietary oils on bile-acid secretion and serum-cholesterol. Lancet, 1, 1090–1092PubMedCrossRefGoogle Scholar
  3. 3.
    Lindstedt, S., Avigan, J., Goodman, D. S., Sjovall, J. and Steinberg, D. (1965). The effect of dietary fat on the turnover of cholic acid and on the composition of the biliary bile acids in man. J. Clin. Invest., 44, 1754–1765PubMedCrossRefGoogle Scholar
  4. 4.
    Pertsemlidis, D., Panveliwalla, D. and Ahrens, E. H. Jr. (1974). Effects of Clofibrate and of an estrogen-progestin combination on fasting biliary lipids and cholic acid kinetics in man. Gastroenterology, 66, 565–573PubMedGoogle Scholar
  5. 5.
    Angelin, B., Einarsson, K. and Leijd, B. (1979). Biliary lipid composition during treatment with different hypolipidaemic drugs. Eur. J. Clin. Invest., 9, 185–190PubMedCrossRefGoogle Scholar
  6. 6.
    Sturdevant, R. A. L., Pearce, M. L. and Dayton, S. (1973). Increased prevalence of cholelithiasis in men ingesting a serum-cholesterol-lowering diet. N. Engl. J. Med., 288, 24–27PubMedCrossRefGoogle Scholar
  7. 7.
    The Coronary Drug Project Research Group (1977). Gallbladder disease as a side effect of drugs influencing lipid metabolism. N. Engl. J. Med., 296, 1185–1190CrossRefGoogle Scholar
  8. 8.
    Cooper, J.,Geizerova, H. and Oliver, M.F. (1975). Clofibrate and gallstones. Lancet, 1, 1083Google Scholar
  9. 9.
    The Committee of Principal Investigators (1978). A co-operative trial in the primary prevention of ischaemic heart disease using Clofibrate. Br. Heart J., 40, 1069–1118CrossRefGoogle Scholar
  10. 10.
    Miettinen, M., Turpeinen, O., Karvonen, M. J., Paavilainen, E. and Elosuo, R. (1976). Prevalence of cholelithiasis in men and women ingesting a serum-cholesterol-lowering diet. Ann. Clin. Res., 8, 111–116PubMedGoogle Scholar
  11. 11.
    W.H.O. European Collaborative Group (1974). An international controlled trial in the multifactorial prevention of coronary heart disease. Int. J. Epidemiol., 3, 219–224CrossRefGoogle Scholar
  12. 12.
    Research Group of the Rome Project of Coronary Heart Disease Prevention (1976). The Rome Project of Coronary Heart Disease Prevention. Ann. Ist. Sup. Sanit., 12, 316–330Google Scholar
  13. 13.
    Mariotti, S., Verdecchia, A., Capocaccia, R., Conti, S., Farchi, G. and Menotti, A. (1977). Identificazione di soggetti ad alto rischio nel Progetto Romano di Prevenzione della Cardiopatia Coronarica. G. Ital. Cardiol., 7, 141–146PubMedGoogle Scholar
  14. 14.
    Gruppo di Ricerca del Progetto Romano di Prevenzione della Cardiopatia Coronarica (1982). Il Progetto Romano di Prevenzione della Cardiopatia Coronarica. Risultati finali. G. Ital. Cardiol., 12, 541–554.Google Scholar

Copyright information

© MTP Press Limited 1984

Authors and Affiliations

  • G. C. Urbinati
  • the GREPCO Group

There are no affiliations available

Personalised recommendations